Determining the Expression Levels of LncRNA PVT1 and MiR-128 in the Human Lung Carcinoma Cell Line

<strong>Objective:</strong> In the presented research, we aimed to examine the expression of microRNA-128 (miR-128) and long non-coding RNA (lncRNA) the plasmacytoma variant translocation 1 (PVT1) in non-cancerous cells BEAS-2B and human lung carcinoma A549 to identify any potential roles these molecules might play in the cancer development in lung tissue. <strong>Material and Methods: </strong>The cell lines used in this research were A549 and BEAS-2B. Total RNA was isolated from these cell lines, and then complementary DNA (cDNA) was synthesised. Using the quantitative real-time PCR (RT-qPCR) method, the expression levels of lncRNA PVT1 and miR-128 were evaluated. The 2-∆∆Ct method was employed to analyse fold changes by normalising to U6 snRNA and GAPDH expressions. <strong>Results:</strong> Elevated PVT1 expression was determined in the lung cancer cells (p&lt;0.01). Nevertheless, miR-128 expression did not change statistically significantly (p&gt;0.05). Even though miR-128 is a potential binding target of lncRNA PVT1 according to in silico analysis, the expression profile does not correlate. <strong>Conclusion:</strong> Our evaluation of the relationship between lncRNA PVT1 and miR-128 in cancerous cells A549 compared with non-cancerous cells BEAS-2B reveals that PVT1 expression is significantly elevated in lung cancer cells, whereas miR-128 expression remains unchanged. Further investigation is needed to explore whether the interaction between lncRNA PVT1 and miR-128 is indirect.&nbsp;